Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool
Carregando...
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
GREBE, Eduard
FACENTE, Shelley N.
BINGHAM, Jeremy
PILCHER, Christopher D.
POWRIE, Andrew
GERBER, Jarryd
PRIEDE, Gareth
CHIBAWARA, Trust
BUSCH, Michael P.
MURPHY, Gary
Citação
BMC INFECTIOUS DISEASES, v.19, n.1, article ID 894, 10p, 2019
Resumo
Background It is frequently of epidemiological and/or clinical interest to estimate the date of HIV infection or time-since-infection of individuals. Yet, for over 15 years, the only widely-referenced infection dating algorithm that utilises diagnostic testing data to estimate time-since-infection has been the 'Fiebig staging' system. This defines a number of stages of early HIV infection through various standard combinations of contemporaneous discordant diagnostic results using tests of different sensitivity. To develop a new, more nuanced infection dating algorithm, we generalised the Fiebig approach to accommodate positive and negative diagnostic results generated on the same or different dates, and arbitrary current or future tests - as long as the test sensitivity is known. For this purpose, test sensitivity is the probability of a positive result as a function of time since infection. Methods The present work outlines the analytical framework for infection date estimation using subject-level diagnostic testing histories, and data on test sensitivity. We introduce a publicly-available online HIV infection dating tool that implements this estimation method, bringing together 1) curatorship of HIV test performance data, and 2) infection date estimation functionality, to calculate plausible intervals within which infection likely became detectable for each individual. The midpoints of these intervals are interpreted as infection time 'point estimates' and referred to as Estimated Dates of Detectable Infection (EDDIs). The tool is designed for easy bulk processing of information (as may be appropriate for research studies) but can also be used for individual patients (such as in clinical practice). Results In many settings, including most research studies, detailed diagnostic testing data are routinely recorded, and can provide reasonably precise estimates of the timing of HIV infection. We present a simple logic to the interpretation of diagnostic testing histories into infection time estimates, either as a point estimate (EDDI) or an interval (earliest plausible to latest plausible dates of detectable infection), along with a publicly-accessible online tool that supports wide application of this logic. Conclusions This tool, available at , is readily updatable as test technology evolves, given the simple architecture of the system and its nature as an open source project.
Palavras-chave
HIV, Infection dating, Infection duration, Infection timing, Diagnostics, Diagnostic assays
Referências
- Ananworanich J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-56
- Delaney KP, 2017, CLIN INFECT DIS, V64, P53, DOI 10.1093/cid/ciw666
- Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005
- Grebe E, 2017, JAIDS-J ACQ IMM DEF, V76, P547, DOI [10.1097/QAI.0000000000001537, 10.1097/qai.0000000000001537]
- Hologic I, 2015, 501623 ROCH MOL DIAL
- Kassanjee R, 2014, CHARACTERISATION APP
- Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
- Keating SM, 2016, JAIDS-J ACQ IMM DEF, V73, P581, DOI 10.1097/QAI.0000000000001146
- Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038
- Masciotra S, 2011, J CLIN VIROL, V52, pS17, DOI 10.1016/j.jcv.2011.09.011
- Murphy G, 2017, EPIDEMIOL INFECT, V145, P925, DOI 10.1017/S0950268816002910
- Owen SM, 2008, J CLIN MICROBIOL, V46, P1588, DOI 10.1128/JCM.02196-07
- Owen SM, 2015, AACC ANN M BIOR IND
- Perry KR, 2008, TRANSFUSION MED, V18, P228, DOI 10.1111/j.1365-3148.2008.00874.x
- Pilcher CD, 2019, AIDS, V33, P1231, DOI [10.1097/QAD.0000000000002190, 10.1097/qad.0000000000002190]
- Roche Molecular Diagnostics GmbH, COBAS AMPLICOR HIV 1